A Comparison Between Chemo-Radiotherapy Combined With Immunotherapy and Chemo-Radiotherapy Alone for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis

The evolution of stereotactic radiosurgery in neurosurgical practice

(2021) Daniel M. Trifiletti et al.   JOURNAL OF NEURO-ONCOLOGY

Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials

(2020) D.E. Magee et al.   ANNALS OF ONCOLOGY

A review of cancer immunotherapy toxicity

(2020) Lucy Boyce Kennedy et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Integration of immuno-oncology with stereotactic radiosurgery in the management of brain metastases

(2020) Eric J. Lehrer et al.   JOURNAL OF NEURO-ONCOLOGY

Awake vs. asleep motor mapping for glioma resection: a systematic review and meta-analysis

(2020) Paola Suarez-Meade et al.   ACTA NEUROCHIRURGICA

Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives

(2020) Bas Weenink et al.   Cancers

Management of glioblastoma: State of the art and future directions

(2020) Aaron C. Tan et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Radiation therapy strategies for skull-base malignancies

(2020) J. D. Palmer et al.   JOURNAL OF NEURO-ONCOLOGY

The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application

(2020) Silvia Minozzi et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer

(2020) Eric J. Lehrer et al.   JAMA Oncology

Current State of Immunotherapy for Treatment of Glioblastoma

(2019) Tresa McGranahan et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Improving attribution of adverse events in oncology clinical trials

(2019) Goldy C. George et al.   CANCER TREATMENT REVIEWS

A Randomized Double-Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell Vaccine ICT-107 In Newly Diagnosed Patients With Glioblastoma

(2019) Patrick Y. Wen et al.   CLINICAL CANCER RESEARCH

CAR T cells for brain tumors: Lessons learned and road ahead

(2019) David Akhavan et al.   IMMUNOLOGICAL REVIEWS

Tumor targeting peptides: novel therapeutic strategies in glioblastoma

(2019) Drazen Raucher   CURRENT OPINION IN PHARMACOLOGY

JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma

(2018) Toshihiko Wakabayashi et al.   JOURNAL OF NEURO-ONCOLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapies: Exploiting the Immune System for Cancer Treatment

(2018) Jeffrey Koury et al.   Journal of Immunology Research

An overview of cancer immunotherapeutic strategies

(2018) Braira Wahid et al.   Immunotherapy

Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data

(2018) Eric J. Lehrer et al.   RADIOTHERAPY AND ONCOLOGY

Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity

(2018) Orneala Bakos et al.   Journal for ImmunoTherapy of Cancer

­­­­Immunotherapy for Glioblastoma: Adoptive T-cell Strategies

(2018) Bryan D. Choi et al.   CLINICAL CANCER RESEARCH

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the Management of Brain Metastases

(2018) Eric Lehrer et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial

(2018) Johanna Buchroithner et al.   Cancers

Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma—A phase II multicentric, randomised study

(2017) Renata Ursu et al.   EUROPEAN JOURNAL OF CANCER

The Safety of available immunotherapy for the treatment of glioblastoma

(2017) S. Harrison Farber et al.   Expert Opinion On Drug Safety

Immunotherapy for Brain Tumors

(2017) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape

(2017) Benjamin M. Ellingson et al.   JOURNAL OF NEURO-ONCOLOGY

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

(2017) Michael Weller et al.   LANCET ONCOLOGY

A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913

(2017) Prakash Chinnaiyan et al.   NEURO-ONCOLOGY

Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications

(2017) Tanner M. Johanns et al.   NEUROSURGERY

CpG and Non-CpG Methylation in Epigenetic Gene Regulation and Brain Function

(2017) et al.   Genes

Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma

(2016) Lee A. Wheeler et al.   NEURO-ONCOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in korea

(2016) Doo-Sik Kong et al.   Oncotarget

Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation

(2016) Aizhen Liu et al.   Frontiers in Oncology

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients

(2015) E. Q. Lee et al.   CLINICAL CANCER RESEARCH

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma

(2015) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cancer immunotherapy: harnessing the immune system to battle cancer

(2015) Yiping Yang   JOURNAL OF CLINICAL INVESTIGATION

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

(2015) Hideho Okada et al.   LANCET ONCOLOGY

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

(2014) Roger Stupp et al.   LANCET ONCOLOGY

Adverse Event Reporting in Cancer Clinical Trial Publications

(2013) Shanthi Sivendran et al.   JOURNAL OF CLINICAL ONCOLOGY

Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas

(2011) Michael A. Vogelbaum et al.   NEUROSURGERY

Adjuvant Immunotherapy with Whole-Cell Lysate Dendritic Cells Vaccine for Glioblastoma Multiforme: A Phase II Clinical Trial

(2011) Der-Yang Cho et al.   World Neurosurgery

The Use of Convection-Enhanced Delivery with Liposomal Toxins in Neurooncology

(2011) Massimo S. Fiandaca et al.   Toxins

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

(2010) J. H. Sampson et al.   NEURO-ONCOLOGY

EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME

(2009) et al.   NEUROSURGERY

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE